Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,6 USD | -3,90% | -1,83% | -8,57% |
Omzet 2024 * | 3,4 mln. 3,17 mln. | Omzet 2025 * | 4,28 mln. 4 mln. | Marktkapitalisatie | 7,12 mln. 6,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -19 mln. -17,73 mln. | Nettowinst (verlies) 2025 * | -22 mln. -20,53 mln. | EV/omzet 2024 * | 2,09 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,66 x |
K/w-verhouding 2024 * |
-0,73
x | K/w-verhouding 2025 * |
-0,88
x | Werknemers | 20 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,77% |
Recentste transcriptie over Plus Therapeutics, Inc.
1 dag | -3,90% | ||
1 week | -1,83% | ||
Lopende maand | -11,35% | ||
1 maand | -13,97% | ||
3 maanden | -22,33% | ||
6 maanden | +48,16% | ||
Lopend jaar | -8,57% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 06-02-20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 27-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Richard Hawkins
CHM | Chairman | 75 | 01-12-07 |
Robert Lenk
BRD | Director/Board Member | 75 | 01-03-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,6 | -3,90% | 2 181 |
25-04-24 | 1,665 | +4,06% | 5 262 |
24-04-24 | 1,6 | -1,84% | 8 544 |
23-04-24 | 1,63 | -1,81% | 17 177 |
22-04-24 | 1,66 | +1,84% | 199 230 |
uitgestelde koers Nasdaq, 26 april 2024 om 15:48 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-8,57% | 7,12 mln. | |
+1,46% | 42,59 mld. | |
+7,70% | 40,65 mld. | |
+48,49% | 40,57 mld. | |
-11,96% | 26,77 mld. | |
+8,03% | 24,81 mld. | |
-24,69% | 18,17 mld. | |
+28,45% | 12,05 mld. | |
-2,89% | 11,7 mld. | |
+7,31% | 11,1 mld. |